Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery

Antonia Molloy; James Harrison; John S. McGrath; Zachary Owen; Clive Smith; Xin Liu; Xin Li; Jonathan A. G. Cox

doi:10.3390/microorganisms9112330

Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery

Antonia Molloy
, James Harrison
, John S. McGrath
, Zachary Owen
, Clive Smith
, Xin Liu
, Xin Li
, Jonathan A. G. Cox^*

^*Corresponding author for this work

School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, U.K.
Sphere Fluidics Limited, The McClintock Building, Suite 7, Granta Park, Great Abington, Cambridge CB21 6GP, UK

Research output: Contribution to journal › Review article › peer-review

18 Citations (SciVal)

40 Downloads (Pure)

Abstract

Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen Mycobacterium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques provide single-cell analysis which reduces experimental time and the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review outlines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculosis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.

Original language	English
Article number	2330
Journal	Microorganisms
Volume	9
Issue number	11
DOIs	https://doi.org/10.3390/microorganisms9112330
Publication status	Published - 11 Nov 2021

Bibliographical note

© 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/)

This research was funded by the EPSRC and SFI Centre for Doctoral Training in Engineered Tissues for Discovery, Industry and Medicine, Grant Number EP/S02347X/1.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antibiotics
Antimicrobial resistance
Bioengineered models
Diagnostics
Drug discovery
Microfluidics
Mycobacterium
Single-cell analysis
Tuberculosis

Access to Document

10.3390/microorganisms9112330Licence: CC BY 3.0

Microfluidics as a Novel Technique for Tuberculosis
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/)
Final published version, 1.66 MBLicence: CC BY 3.0

Cite this

@article{0274cbda6d1f4f9eb642b92c254240c3,

title = "Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery",

abstract = "Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen Mycobacterium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques provide single-cell analysis which reduces experimental time and the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review outlines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculosis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.",

keywords = "Antibiotics, Antimicrobial resistance, Bioengineered models, Diagnostics, Drug discovery, Microfluidics, Mycobacterium, Single-cell analysis, Tuberculosis",

author = "Antonia Molloy and James Harrison and McGrath, \{John S.\} and Zachary Owen and Clive Smith and Xin Liu and Xin Li and Cox, \{Jonathan A. G.\}",

note = "{\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/) This research was funded by the EPSRC and SFI Centre for Doctoral Training in Engineered Tissues for Discovery, Industry and Medicine, Grant Number EP/S02347X/1. ",

year = "2021",

month = nov,

day = "11",

doi = "10.3390/microorganisms9112330",

language = "English",

volume = "9",

journal = "Microorganisms",

issn = "2076-2607",

publisher = "Multidisciplinary Digital Publishing Institute",

number = "11",

}

TY - JOUR

T1 - Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery

AU - Molloy, Antonia

AU - Harrison, James

AU - McGrath, John S.

AU - Owen, Zachary

AU - Smith, Clive

AU - Liu, Xin

AU - Li, Xin

AU - Cox, Jonathan A. G.

N1 - © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/) This research was funded by the EPSRC and SFI Centre for Doctoral Training in Engineered Tissues for Discovery, Industry and Medicine, Grant Number EP/S02347X/1.

PY - 2021/11/11

Y1 - 2021/11/11

N2 - Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen Mycobacterium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques provide single-cell analysis which reduces experimental time and the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review outlines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculosis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.

AB - Tuberculosis (TB) remains a global healthcare crisis, with an estimated 5.8 million new cases and 1.5 million deaths in 2020. TB is caused by infection with the major human pathogen Mycobacterium tuberculosis, which is difficult to rapidly diagnose and treat. There is an urgent need for new methods of diagnosis, sufficient in vitro models that capably mimic all physiological conditions of the infection, and high-throughput drug screening platforms. Microfluidic-based techniques provide single-cell analysis which reduces experimental time and the cost of reagents, and have been extremely useful for gaining insight into monitoring microorganisms. This review outlines the field of microfluidics and discusses the use of this novel technique so far in M. tuberculosis diagnostics, research methods, and drug discovery platforms. The practices of microfluidics have promising future applications for diagnosing and treating TB.

KW - Antibiotics

KW - Antimicrobial resistance

KW - Bioengineered models

KW - Diagnostics

KW - Drug discovery

KW - Microfluidics

KW - Mycobacterium

KW - Single-cell analysis

KW - Tuberculosis

UR - https://www.mdpi.com/2076-2607/9/11/2330

UR - https://www.scopus.com/pages/publications/85118712523

U2 - 10.3390/microorganisms9112330

DO - 10.3390/microorganisms9112330

M3 - Review article

SN - 2076-2607

VL - 9

JO - Microorganisms

JF - Microorganisms

IS - 11

M1 - 2330

ER -

Microfluidics as a Novel Technique for Tuberculosis: From Diagnostics to Drug Discovery

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this